U.S.-Cuba collaborations on life sciences projects keep making news.
August, I wrote a special report for Bloomberg BNA and blogged about innovations
developed in Cuba as result of the country’s need to create its own life
sciences industry due to the U.S. trade embargo of Cuba. I noted U.S.
companies and nonprofits have been
the few time-intensive mechanisms that have existed until now to
pursue U.S.-Cuba collaborations for these projects.
weeks ago, I wrote an article and blogged about the Oct. 14
White House announcement that the Treasury Department's Office of Foreign
Assets Control (OFAC) will permit approval of Cuban
pharmaceuticals by the Food and Drug Administration and will allow them to be
imported for marketing, sale and distribution. OFAC will also allow individuals
subject to U.S. jurisdiction to engage in joint medical research projects with
Then on Oct. 28, the FDA announced it approved a U.S. clinical trial of the CimaVax treatment for non-small cell lung cancer developed by Cuba’s Center of Molecular Immunology (CMI). The clinical trial, which will be held at the Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., will examine the efficacy of the vaccine, which has previously shown improvement in overall survival for lung cancer patients in comparison with a control group.
RPCI representatives at the BIO 2016 International Convention in San Francisco discussed how they had received an OFAC license to work with the CMI on CimaVax and the RPCI’s efforts to obtain approval for a U.S. clinical trial. And now the clinical trial is going to begin.
U.S. companies and non
have expressed interest in collaborating with the Cuban government and Cuban
companies on other drugs and vaccines that I discussed in the special report
for marketing in the U.S.
I am looking forward to seeing how their efforts progress in this new environment.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)